Company Filing History:
Years Active: 2001-2007
Title: Brian Colin Rodgers: Innovator in Viral Polypeptide Research
Introduction
Brian Colin Rodgers is a notable inventor based in Kent, GB. He has made significant contributions to the field of viral polypeptides, holding two patents that focus on post-transfusional non-A non-B hepatitis. His work has implications for diagnostic assays and vaccine formulations, showcasing his commitment to advancing medical science.
Latest Patents
Rodgers' latest patents include innovations related to viral agents and PT-NANB hepatitis polypeptides. The first patent addresses the post-transfusional non-A non-B hepatitis viral polypeptide, along with DNA sequences encoding such viral polypeptides. It also covers expression vectors containing these DNA sequences and hosts transformed by such vectors. The second patent mirrors the first, emphasizing the use of these polypeptides in diagnostic assays and vaccine formulations.
Career Highlights
Brian Colin Rodgers is associated with Glaxo Wellcome Inc., where he has been able to apply his expertise in virology and biotechnology. His work has contributed to the understanding and potential treatment of hepatitis, a significant public health concern.
Collaborations
Rodgers has collaborated with esteemed colleagues such as Peter Edmund Highfield and Richard Seton Tedder. These partnerships have likely enhanced the scope and impact of his research.
Conclusion
Brian Colin Rodgers stands out as an innovator in the field of viral polypeptide research, with patents that hold promise for improving diagnostic and therapeutic approaches to hepatitis. His contributions continue to influence the medical community and advance scientific knowledge.